Physician profile
Ronald E Weiner
NPI 1629082862
$751.74
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.54 · 2020: $18.22 · 2021: $29.86 · 2022: $265 · 2023: $241 · 2024: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $349.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $133.40 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $87.62 | 2019-2024 | Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $77.50 | 2022-2023 | Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $73.76 | 2023-2024 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $73.05 | 2022-2023 | |
| Genentech USA, INC. | $47.08 | 2022-2024 | Xolair |
| Covis Pharma Gmbh | $43.46 | 2022 | |
| Hikma Pharmaceuticals USA | $35.02 | 2023 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $33.00 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $31.20 | 2022 | |
| Optinose US, INC. | $30.81 | 2019 | |
| Merck Sharp & Dohme LLC | $29.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.60 | 2023 | Takhzyro |
| Kaleo, INC. | $17.04 | 2022 | |
| Pharming Healthcare, INC. | $13.34 | 2023 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.